Efficacy and Safety of Camrelizumab in Combination with Docetaxel + S-1 Sequenced by Camrelizumab + S-1 for Stage III (PD-1+/MSI-H/EBV+/dMMR) Gastric Cancer: Study Protocol for a Single-Center, Prospective, Open-Label, Single-Arm Trial

BackgroundGastric cancer occupies the fourth highest morbidity rate of cancers worldwide. A higher incidence of gastric cancer had been found in East Asia compared to the other regions. Gastrectomy with radical lymph node dissection is the cornerstone of curative treatment for Stage III gastric canc...

詳細記述

書誌詳細

出版年:	Frontiers in Surgery
主要な著者:	Zhongyi Dong, Bo Ni, Linxi Yang, Yujing Guan, Chunchao Zhu, Enhao Zhao, Gang Zhao, Xiang Xia, Zizhen Zhang
フォーマット:	論文
言語:	英語
出版事項:	Frontiers Media S.A. 2022-06-01
主題:	camrelizumab docetaxel gastric cancer S-1 clinical protocols
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fsurg.2022.917352/full